Journal Image
Current Vascular Pharmacology
ISSN (Print): 1570-1611
ISSN (Online): 1875-6212
Epub Full Text Article
DOI: 10.2174/15701611113116660166      Price:  $95

Lipoproteins, Stroke and Statins

Author(s): Livia Pisciotta, Stefano Bertolini and Aldo Pende
Dyslipidemia represents one of the major risk factors for atherosclerosis affecting the arteries of large and medium caliber and consequently causing ischemia in the brain, heart, or legs. Coronary artery disease and cerebral stroke represent the major causes of morbidity and mortality among the elderly and middle aged subjects. The change of lifestyle can reduce the risk of cardiovascular disease but available drug therapy (in particular statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase) is effective in modifying hyperlipidemia and consequently reducing cardiovascular events. The hypolipemic drugs can prevent, slow the progression and sometimes determine the regression of atherosclerotic plaques, therefore significantly reducing the clinical complications of atherosclerotic cardiovascular disease. In this review, we want to point out the role of the different lipoproteins, such as triglycerides, HDL-C, LDL-C, Lp(a), in the pathogenesis of stroke and the role of statins in reducing both lipid fractions and stroke risk.
Cardiovascular risk, dyslipidemias, lipid lowering therapy, lipoproteins, statins, stroke
Clinic of Internal Medicine 1, University of Genoa School of Medicine, Viale Benedetto XV 6, 16132 Genoa, Italy.